PHARMACOKINETIC EVALUATION OF A
NOVEL RUTHENIUM (III)-OFLOXACIN
COMPLEX, AS POTENTIAL THERAPEUTIC
AGENT
BRUNO STEFAN VELESCU1, VALENTINA ANUŢA2*, VALENTINA
UIVAROŞI3
1Department of Pharmacology and Clinical Pharmacy, Faculty of
Pharmacy, “Carol Davila” University of Medicine and Pharmacy, 6
Traian Vuia, 020956 Bucharest, Romania
2Department of Physical chemistry, Faculty of Pharmacy, “Carol
Davila” University of Medicine and Pharmacy, 6 Traian Vuia, 020956
Bucharest, Romania
3Department of Inorganic Chemistry, Faculty of Pharmacy, “Carol
Davila” University of Medicine and Pharmacy, 6 Traian Vuia, 020956
Bucharest, Romania
* corresponding author: vali_anuta@yahoo.com
Download Full Article

Abstract:

The aim of the study was to investigate the pharmacokinetic profile of a novel
ruthenium (III)-ofloxacin complex, with the general formula [Ru(oflo)2Cl3(DMSO)] and
the released ofloxacin in an animal experimental model, following a single dose of 100
mg/kg b.w., intraperitoneally administered. A HPLC method for the simultaneous
quantification of the ruthenium-ofloxacin complex and ofloxacin from rat plasma was
developed and validated according to the international guidelines. The method was applied
in the pharmacokinetic study. The sample analyses allowed estimating both complex and
released ofloxacin pharmacokinetic profile. Both complex and released ofloxacin kinetics
are described by a bicompartmental model. The obtained results suggest a pharmacokinetic
profile of the complex suitable for a distribution in the animal organism.

Top